$10.69−0.87 (−7.53%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
ArriVent BioPharma (AVBP) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
5 figures withheld by our checks. Each blank figure names its reason.
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld.
The lines that matter · FY23–FY25
Revenue ($M)—
0.0
FY23→FY25CAGR —
Net income ($M)▼106.6%
−166.3
FY23→FY25CAGR —
Diluted EPS▼68.8%
−4.32
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level
This filer reports no gross profit or operating income line, so those margins are not drawn.
The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7766, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 5.0 | 0.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | 0.0 | 0.0 | 0.0 | — | — |
Research & development | 151.0 | 153.4 | 79.0 | 64.9 | ▲94.1% | +53.7% |
Selling, general & admin | 35.0 | 24.2 | 15.3 | 9.7 | ▲58.0% | +57.8% |
Total operating expenses | 186.0 | 177.5 | 94.3 | 74.6 | ▲88.2% | +54.3% |
Operating incomefeeds ROC rank | −181.0 | −177.5 | −94.3 | −74.6 | ▼88.2% | — |
Other income, net | 11.9 | 11.2 | 13.8 | 5.3 | — | — |
Pretax income | −169.1 | −166.3 | −80.5 | −69.3 | ▼106.6% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −169.1 | −166.3 | −80.5 | −69.3 | ▼106.6% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −3.51 | −4.32 | −2.56 | −32.38 | ▼68.8% | — |
Diluted shares (mn) | 49.53 | 38.46 | 31.47 | 2.14 | ▲22.2% | +323.9% |
| Margins | ||||||
Gross margin | —A | — | — | — | — | — |
Operating margin | −3620.0% | — | — | — | — | — |
Net margin | −3381.4% | — | — | — | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-05 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

